Literature DB >> 7637352

A randomized study of the influence of perfusion technique and pH management strategy in 316 patients undergoing coronary artery bypass surgery. II. Neurologic and cognitive outcomes.

J M Murkin1, J S Martzke, A M Buchan, C Bentley, C J Wong.   

Abstract

UNLABELLED: This double-blind, randomized comparison of pulsatile or nonpulsatile perfusion and alpha-stat or pH-stat management during cardiopulmonary bypass was designed to assess postoperative central nervous system outcomes.
METHODS: Neurologic and cognitive testing was conducted before the operation and 7 days and 2 months after the operation in 316 patients having coronary artery bypass and in a reference cohort of 40 patients having major vascular and thoracic operations.
RESULTS: As detailed in part I of this study, mortality in patients having coronary bypass was 2.8%. The incidence of stroke was 2.5% and did not differ among bypass groups. Mortality was 2.5% for the major surgery cohort. The incidence of cognitive (p = 0.003) and either neurologic or cognitive dysfunction (p = 0.0002) was higher at 7 days for the coronary bypass group than for the major surgery cohort. The incidence of neurologic dysfunction remained higher (p = 0.050) at 2 months in the coronary bypass group. Cognitive dysfunction at 2 months was less prevalent after 90 minutes of cardiopulmonary bypass in patients managed with alpha-stat than with pH-stat strategy (27% versus 44%, p = 0.047).
CONCLUSIONS: Postoperative central nervous system dysfunction is more prevalent in patients having coronary bypass than in those having major operations. Pulsatility has no effect on central nervous system outcomes, but alpha-stat management is associated with a decreased incidence of cognitive dysfunction in patients undergoing prolonged cardiopulmonary bypass.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7637352     DOI: 10.1016/S0022-5223(95)70230-X

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  27 in total

Review 1.  Postoperative Cognitive Dysfunction: Minding the Gaps in Our Knowledge of a Common Postoperative Complication in the Elderly.

Authors:  Miles Berger; Jacob W Nadler; Jeffrey Browndyke; Niccolo Terrando; Vikram Ponnusamy; Harvey Jay Cohen; Heather E Whitson; Joseph P Mathew
Journal:  Anesthesiol Clin       Date:  2015-07-16

2.  The benefits of cognitive training after a coronary artery bypass graft surgery.

Authors:  Emilie de Tournay-Jetté; Gilles Dupuis; André Denault; Raymond Cartier; Louis Bherer
Journal:  J Behav Med       Date:  2011-11-09

3.  Patient selection and technical considerations for off-pump coronary surgery.

Authors:  Amit N Patel; Federico Benetti; Baron Hamman
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-07

Review 4.  What blood pressure is appropriate for cardiopulmonary bypass and how to get it.

Authors:  Alan Merry
Journal:  J Extra Corpor Technol       Date:  2006-03

5.  [Cognitive deterioration after cardiosurgery].

Authors:  N Schwarz; M Schönburg; S Kastaun; T Gerriets; M Kaps
Journal:  Nervenarzt       Date:  2011-02       Impact factor: 1.214

Review 6.  Neuroprotective Strategies in Repair and Replacement of the Aortic Arch.

Authors:  Frank Manetta; Clancy W Mullan; Michael A Catalano
Journal:  Int J Angiol       Date:  2018-05-27

Review 7.  A risk-benefit assessment of aprotinin in cardiac surgical procedures.

Authors:  W B Dobkowski; J M Murkin
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

8.  Perspective on Cerebral Microemboli in Cardiac Surgery: Significant Problem or Much Ado About Nothing?

Authors:  Simon J Mitchell; Alan F Merry
Journal:  J Extra Corpor Technol       Date:  2015-03

Review 9.  [Perioperative stroke].

Authors:  M Fischer; U Kahl
Journal:  Anaesthesist       Date:  2021-01       Impact factor: 1.041

10.  Microemboli in our bypass circuits: a contemporary audit.

Authors:  Timothy W Willcox; Simon J Mitchell
Journal:  J Extra Corpor Technol       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.